Yuzi Zhang

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.

Journal: Pathology oncology research : POR

Published: February 16, 2022

Hybrid Capture-based Genomic Profiling of Circulating Tumor DNA From Patients With Advanced Ovarian Cancer.

Hybrid Capture-based Genomic Profiling of Circulating Tumor DNA From Patients With Advanced Ovarian Cancer.

Journal: Pathology oncology research : POR

Published: July 09, 2020

Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan-cancer analysis.

Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan-cancer analysis.

Journal: Molecular genetics & genomic medicine

Published: July 07, 2020

Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients.

Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients.

Journal: Journal of Cancer

Published: June 09, 2020

Landscape of RAS Variations in 17,993 Pan-cancer Patients Identified by Next-generation Sequencing.

Landscape of RAS Variations in 17,993 Pan-cancer Patients Identified by Next-generation Sequencing.

Journal: Pathology oncology research : POR

Published: May 25, 2020

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report.

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report.

Journal: Medicine

Published: May 24, 2020

Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.

Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.

Journal: Therapeutic advances in medical oncology

Published: January 15, 2020

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.

Journal: JAMA oncology

Published: December 27, 2019

Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC.

Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 04, 2019

Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing.

Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing.

Journal: Oncology

Published: December 02, 2019

Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.

Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.

Journal: Cancer medicine

Published: November 27, 2019

Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.

Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: July 28, 2019

Showing 1-12 of 23

Last Updated: 09/26/2026